Sensitivity and resistance to DNA damage response inhibitors in acute myeloid leukemia with spliceosome mutations

Description of the granted funding

Acute myeloid leukemia (AML) is an aggressive blood cancer treated with combination chemotherapy. The development of therapy for AML has been slow, and the standard chemotherapy has remained unchanged for decades. Spliceosome mutations are recurrent drivers of AML pathogenesis. Recent research shows that spliceosome mutations induce a DNA damage response vulnerability that can be targeted therapeutically. This study identifies new drug sensitivities in spliceosome mutated AML.
Show more

Starting year

2020

End year

2024

Granted funding

Samuli Eldfors Orcid -palvelun logo
297 957 €

Funder

Research Council of Finland

Funding instrument

Postdoctoral Researcher

Other information

Funding decision number

334273

Fields of science

Biomedicine

Research fields

Biolääketieteet

Identified topics

cancer